Interestingly, in the post-hoc analysis of the PETACC-8 trial [24], it was reported that in the MSI-H subpopulation, the presence of BRAF V600E mutation was associated with longer DFS as compared to BRAF-WT patients, but there was no effect on OS (DFS: HR 0.23, 95% CI 0.06–0.92, p = 0.04; OS: HR 0.19, 95% CI 0.03–1.24, p = 0.08), suggesting that MSI-H is a protective factor against BRAF mutation in early-stage CRC. The gene discussed is BRAF; the disease is colorectal carcinoma.